Patritumab: Ph II ongoing

Daiichi said patritumab will be evaluated in the ongoing Phase II I-SPY 2 trial, which is designed to rapidly and inexpensively test compounds in biomarker-defined subgroups of patients with neoadjuvant breast cancer. The program uses Bayesian statistics to predict specific groups in which a compound has an 85% chance of success in a Phase III trial. Patritumab will be evaluated in combination with trastuzumab and paclitaxel. Daiichi and Amgen are partnered to co-develop patritumab...